Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest Expenses (2016 - 2025)

China Pharma Holdings filings provide 16 years of Interest Expenses readings, the most recent being $6879.0 for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 1.13% to $6879.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $27243.0, a 0.4% change, with the full-year FY2025 number at $27272.0, changed 0.3% from a year prior.
  • Interest Expenses hit $6879.0 in Q4 2025 for China Pharma Holdings, up from $6798.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $245056.0 in Q4 2021 to a low of -$252776.0 in Q4 2023.
  • Median Interest Expenses over the past 5 years was $6847.5 (2024), compared with a mean of $11515.4.
  • The widest YoY moves for Interest Expenses: up 2969.86% in 2022, down 199.81% in 2022.
  • China Pharma Holdings' Interest Expenses stood at $245056.0 in 2021, then crashed by 199.81% to -$244593.0 in 2022, then fell by 3.35% to -$252776.0 in 2023, then skyrocketed by 102.69% to $6802.0 in 2024, then increased by 1.13% to $6879.0 in 2025.
  • The last three reported values for Interest Expenses were $6879.0 (Q4 2025), $6798.0 (Q3 2025), and $6779.0 (Q2 2025) per Business Quant data.